Japanese Device Makers Unite To Develop Heart Pump In U.S.
This article was originally published in PharmAsia News
Executive Summary
Japanese medical device makers Asahi Kasei and Misuzu & Sun Medical Holdings have entered into an agreement to develop and market Misuzu's implantable heart-assist device in the United States and elsewhere. Under the agreement, Asahi Kasei bought a 60 percent stake in Misuzu's U.S. subsidiary, Evaheart Medical USA for $7.5 million and is to cover the cost of clinical trials in the United States. The device under development is Misuzu's left ventricular assist system that helps the heart circulate blood via an implantable pump. The firm already has applied for approval in Japanese. (Click here for more - a subscription may be required)
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.